Navigation Links
Sumagen Initiates Clinical Testing of Omnia Biologics Manufactured HIV Vaccine

ROCKVILLE, Md., Jan. 10, 2012 /PRNewswire/ -- Biologics drug development and manufacturing services provider Omnia Biologics, Inc. (Omnia) (Rockville, MD) today announced that its customer Sumagen, Co., Ltd., (Seoul, S. Korea and London, ON) will begin clinical trials of their revolutionary HIV vaccine design. The Food and Drug Administration approved Phase I clinical trial will begin in January.

The design and testing of the vaccine was spearheaded by Dr. Chil-Yong Kang, a professor at University of Western Ontario's (UWO) medical school. Dr. Dale VanderPutten of Omnia Biologics commented on the development, "To date experimental HIV vaccines have been largely either subunit vaccines or used non-HIV vaccine vectors and have universally failed in the clinic.  Dr. Kang and his team took a page from the successes of polio, flu, rabies and other highly effective vaccines focusing instead on a viral vaccine that is genetically attenuated, irradiated and chemically inactivated."

Omnia participated in the international effort to propel this important advance into the clinic by providing process and assay development services and manufacturing the vaccine under GMP for South Korean biotech company Sumagen Co. Ltd and their academic partner Dr. Kang and UWO.  Preclinical testing has shown the vaccine to be safe and produce strong immune responses.

Steve Hubert, Vice-President of Operations at Omnia commented on his team's success, "It is especially heartening for our team at Omnia to be able to translate this important technology into the clinic as other well established contract manufacturers failed in their attempts to produce the vaccine at clinical scale."

About Omnia Biologics:  (

Omnia offers translational medicine services in the areas of process development, assay development, GMP manufacture, and fill-finish for preclinical and clinical programs for novel therapeutics platforms.  These include vaccines, autologous therapeutics, new gene therapy platforms, and stem cell technologies.  The company seeks and has established relationships with both biopharmaceutical companies and academic investigators throughout the world.

SOURCE Omnia Biologics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pfizer Initiates Phase 1 Clinical Trial for FVIIa Hemophilia Drug Candidate Developed by Catalyst Biosciences
2. Zimmer Initiates Quarterly Dividend and Announces New Share Repurchase Program
3. Isis Initiates Phase 1 Clinical Study of ISIS-SMNRx in Patients With Spinal Muscular Atrophy
4. Soligenix Initiates Next Generation Anthrax Vaccine Development Program Under Agreement With Harvard University
5. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121 in Combination with Cetuximab and Irinotecan in Patients with Advanced Cancers
6. Regulus Therapeutics Initiates an Orphan and Rare Disease microRNA Therapeutic Effort in Brain Cancer
7. Spring Creek Healthcare Systems Initiates Strategy to Partner and License DelRX Patents
8. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Combination Study of MM-121 and Multiple Anticancer Therapies in Patients with Advanced Solid Tumors
9. BioMarin Initiates Phase 2 Study for GALNS in Patients Under Five Years of Age With MPS IVA
10. Inspiration Biopharmaceuticals Initiates Second Pivotal Clinical Study of Innovative Hemophilia Therapy OBI-1
11. Cara Therapeutics Initiates Phase I Study with Oral Formulation of Novel Peripherally-Acting Kappa Opioid Agonist
Post Your Comments:
(Date:6/26/2016)... 2016 Jazz Pharmaceuticals plc (Nasdaq: ... Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), ... Inc. ("Celator"; Nasdaq: CPXX ) expired effective ... As previously announced on May 31, 2016, ... agreement under which Jazz Pharmaceuticals has commenced a tender ...
(Date:6/26/2016)... , June 26, 2016 ... value-based care operating models within the health care industry ... greater financial efficiency , Deloitte offers a suite ... key business issues impacting efficient cost optimization: labor resource ... , These services facilitate better outcomes and better economics ...
(Date:6/24/2016)... N.J. , June 24, 2016  Collagen ... the design, development and manufacturing of collagen and ... regeneration announced today that Bill Messer ... and Marketing to further leverage the growing portfolio ... medical devices. Bill joins the Collagen ...
Breaking Medicine Technology:
(Date:6/24/2016)... , ... June 24, 2016 , ... Marcy was in a crisis. Her son James, ... out at his family verbally and physically. , “When something upset him, he couldn’t control ... use it. He would throw rocks at my other children and say he was going ...
(Date:6/24/2016)... ... 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 ... by their peers for this recognition are considered among the top 2 percent of ... honors as members of this year’s Legal Elite Hall of Fame: Miami Shareholders ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San ... Society and the Road To Recovery® program to drive cancer patients to and from ... adults to ensure the highest quality of life and ongoing independence. Getting to ...
(Date:6/24/2016)... ... ... People across the U.S. are sharpening their pencils and honing their writing skills ... patients and their families pay tribute to a genetic counselor by nominating him or ... Counselors (NSGC) Annual Education Conference (AEC) this September. , In April, Genome magazine ...
(Date:6/24/2016)... NY (PRWEB) , ... June 24, 2016 , ... ... Haute Living, is proud to recognize Dr. Barry M. Weintraub as a prominent ... “the most beautiful women in the world, and the most handsome men, look ...
Breaking Medicine News(10 mins):